Sugi Predict

Sugi Predict / Compounds / SCHEMBL17798167

SCHEMBL17798167

SCHEMBL17798167

CCNc1nc2ncc(-c3c(C)noc3C)cc2n1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 16/20 0.53
▸ CYP1A2 P05177 3/20 0.45
▸ TSHR P16473 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ EP300 Q09472 1/20 0.43
▸ CREBBP Q92793 1/20 0.43
▸ ALOX15 P16050 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ BRD2 P25440 1/20 0.42
▸ BRD3 Q15059 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29920673 1.00 BRD4 (0.53) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL29920781 0.93 BRD4 (0.53) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL17797974 0.93 BRD4 (0.53) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL24728185 0.90 BRD4 (0.51) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL17798002 0.90 BRD4 (0.54) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL29921081 0.90 BRD4 (0.54) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL17798053 0.90 BRD4 (0.50) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL24728592 0.90 BRD4 (0.50) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL29921120 0.90 BRD4 (0.50) BRD4CYP1A2TSHRALDH1A1CYP3A4
SCHEMBL17798028 0.89 BRD4 (0.49) BRD4CYP1A2TSHRALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3010503-B1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD (CA) 2020-03-11 — — EP claimed
US-10363257-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2019-07-30 — — US claimed
US-10010556-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2018-07-03 — — US claimed
US-20180161337-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS RVX THERAPEUTICS INC. (CA) 2018-06-14 — — US claimed
US-20170216301-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD. 2017-08-03 — — US claimed
US-9663520-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2017-05-30 — — US claimed
US-20160159801-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. 2016-06-09 — — US claimed
CN-112912077-B Combination therapy for the treatment of triple negative breast cancer 恒翼生物医药(上海)股份有限公司 2023-04-04 — — CN disclosed
CN-112912075-B Combination therapy for the treatment of prostate cancer 恒翼生物医药(上海)股份有限公司 2023-04-04 — — CN disclosed
CN-112912078-B Combination therapy for the treatment of estrogen receptor positive breast cancer 恒翼生物医药(上海)股份有限公司 2023-04-04 — — CN disclosed
WO-2023049257-A1 METHODS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER IN PRE-SELECTED PATIENT POPULATIONS WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A PARP INHIBITOR ZENITH EPIGENETICS LTD. (CA) 2023-03-30 — — WO disclosed
US-11607405-B2 Combination therapy for the treatment of triple-negative breast cancer ZENITH EPIGENETICS LTD. (CA) 2023-03-21 — — US disclosed
EP-3674300-B1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD (CA) 2022-10-12 — — EP disclosed
US-20170216301-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD. 2017-08-03 — — US disclosed
US-9663520-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2017-05-30 — — US disclosed
US-9663520-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2017-05-30 — — US disclosed
US-9663520-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2017-05-30 — — US disclosed
US-20160159801-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. 2016-06-09 — — US disclosed
US-20160159801-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. 2016-06-09 — — US disclosed
US-20160159801-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10363257-B2 Bicyclic bromodomain inhibitors BRD4, BRD3, BRD2 BRD4 1/4885CYP1A2 4220/4885TSHR 3290/4885
US-10010556-B2 Bicyclic bromodomain inhibitors BRD4, BRD3, BRD2 BRD4 1/4885CYP1A2 4220/4885TSHR 3290/4885
US-20180161337-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 BRD4 1/4885CYP1A2 4563/4885TSHR 3575/4885
US-11607405-B2 Combination therapy for the treatment of triple-negative breast cancer BRD4, PARP1, BRD3 BRD4 1/4885CYP1A2 3996/4885TSHR 760/4885
US-20170216301-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 BRD4 1/4885CYP1A2 4563/4885TSHR 3575/4885
US-20160159801-A1 NOVEL BICYCLIC BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 BRD4 1/4885CYP1A2 4563/4885TSHR 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.